Acura Pharmaceuticals, Inc. (ACUR)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Robert B. Jones | CEO, President & Director | 150k | -- | 1959 |
Mr. Peter A. Clemens | Senior VP, CFO & Secretary | 200k | -- | 1953 |
Mr. Robert A. Seiser CPA, Ph.D. | VP, Treasurer & Corporate Controller | 210.2k | 3.24k | 1964 |
Acura Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 9
Description
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Corporate Governance
Recent Events
- Mar 26, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 10, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available